Cagrilintide

Cagrilintide is a weekly weight-loss shot. It copies a natural hormone called amylin.

Amylin is different from GLP-1, the hormone in shots like Ozempic. Amylin helps tell your brain you are full through its own path. So cagrilintide turns up the "I am full" signal a different way.

You will often hear the name "CagriSema." That is just cagrilintide plus semaglutide, two shots used together. It is sold "for research only" because it is not approved yet.

People use it to lose weight. Most use it as a partner to semaglutide, not alone.

The idea is that hitting two different hunger paths works better than one.

It is not for first-timers. If you have never tried a single weight-loss shot, start there first.

The combo data looks decent, but it is not approved.

On its own, a phase 2 trial of 706 people showed about 10.8% weight loss at 26 weeks. The big combo trial, REDEFINE-1, showed about 22.7% weight loss at 68 weeks.

Here is the funny part. Wall Street called that 22.7% a letdown, because they expected even more. So it works, but it did not blow past tirzepatide, which is already approved.

You take it as a small shot under the skin, once a week.

The trials used 2.4 mg of cagrilintide and 2.4 mg of semaglutide each week. That 2.4 to 2.4 ratio is the one with real trial data behind it.

This is the big trap for people who mix their own. Some research powders ship at made-up ratios like 5 to 1. None of those were ever studied. Wrong ratio means you are running an unknown experiment with the same side effects.

The side effects are the same as other weight-loss shots in this class. Mostly stomach problems: feeling sick, throwing up, diarrhea, or being backed up. They are usually worst right after a dose increase.

Two bigger things to flag. Skip it if you or close family have had a rare thyroid cancer called medullary thyroid carcinoma. And mixing it at the wrong ratio is the main failure here, because if a combo is not 2.4 to 2.4, the dose has no trial behind it.

Talk to a real doctor before trying it. We are not your doctor.

Here are the ways people get it, from safest to riskiest.

• Brand. There is none yet. The combo (CagriSema) is under review and not approved.
• Compounded. Some pharmacies ship it for $200 to $500 a month, but the legal ground is shaky since it is not approved.
• Research-only (RUO). The main supply for now, about $80 to $150 a month. Sold "for research only." No purity promise.
• Gray market. Cheapest, about $22 to $25 a month, paid by crypto. Since it is pre-approval, identity is very hard to verify. There are no reference standards yet.